Radgocitabine is a Small Molecule owned by Delta-Fly Pharma, and is involved in 4 clinical trials, of which 2 were completed, and 2 are ongoing.

Radgocitabine (DFP-10917) acts as an anti mitotic agent. It arrests G2/M phase in cell cycle. DFP-10917 is converted to its nucleotide form and gets incorporated into tumor DNA to cause DNA strand break which results in G2/M phase-arrest by cell-checkpoint regulators and ultimately the apoptosis of tumor cells.

The revenue for Radgocitabine is expected to reach a total of $237m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Radgocitabine NPV Report.

Radgocitabine is originated and owned by Delta-Fly Pharma. Nippon Shinyaku is the other company associated in development or marketing of Radgocitabine.

Radgocitabine Overview

Radgocitabine (DFP-10917) is under development for the treatment of relapsed and refractory acute leukemias including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). The drug candidate is administered as an intravenous infusion. It is a deoxycytidine analog that targets G2/M phase of the cell cycle.

Nippon Shinyaku Overview

Nippon Shinyaku develops, manufactures, and sells ethical pharmaceuticals and functional foods. The company offers a wide range of products including drugs for pain, inflammation, and allergies; urological diseases; hematologic malignancies; gastrointestinal disorders; cardiovascular and metabolic diseases among others. Nippon Shinyaku also provides functional food ingredients including health food ingredients, preservatives, spices and condiments, and protein preparations. Its functional food products find application in meat processing, fish processing, dairy product, prepared food, confectionery and bakery, and beverage, among others. The company operates business through a network of offices and research laboratories located in Japan, China, the UK and the US. Nippon Shinyaku is headquartered in Minami-ku, Kyoto, Japan.

The company reported revenues of (Yen) JPY137,484 million for the fiscal year ended March 2022 (FY2022), an increase of 12.8% over FY2021. In FY2022, the company’s operating margin was 20.6%, compared to an operating margin of 21.4% in FY2021. In FY2022, the company recorded a net margin of 16.8%, compared to a net margin of 17% in FY2021. The company reported revenues of JPY35,517 million for the second quarter ended September 2022, a decrease of 0.3% over the previous quarter.

Quick View – Radgocitabine

Report Segments
  • Innovator
Drug Name
  • Radgocitabine
Administration Pathway
  • Parenteral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.